Literature DB >> 27471632

Tumor-infiltrating HLA-matched CD4(+) T cells retargeted against Hodgkin and Reed-Sternberg cells.

Benjamin Rengstl1, Frederike Schmid1, Christian Weiser1, Claudia Döring1, Tim Heinrich1, Kathrin Warner2, Petra S A Becker3, Robin Wistinghausen1, Sima Kameh-Var1, Eva Werling1, Arne Billmeier1, Christian Seidl3, Sylvia Hartmann1, Hinrich Abken4, Ralf Küppers5, Martin-Leo Hansmann1, Sebastian Newrzela1.   

Abstract

Hodgkin lymphoma (HL) presents with a unique histologic pattern. Pathognomonic Hodgkin and Reed-Sternberg (HRS) cells usually account for less than 1% of the tumor and are embedded in a reactive infiltrate mainly comprised of CD4(+) T cells. HRS cells induce an immunosuppressive microenvironment and thereby escape antitumor immunity. To investigate the impact of interactions between HRS cells and T cells, we performed long-term co-culture studies that were further translated into a xenograft model. Surprisingly, we revealed a strong antitumor potential of allogeneic CD4(+) T cells against HL cell lines. HRS and CD4(+) T cells interact by adhesion complexes similar to immunological synapses. Tumor-cell killing was likely based on the recognition of allogeneic major histocompatibility complex class II (MHC-II) receptor, while CD4(+) T cells from MHC-II compatible donors did not develop any antitumor potential in case of HL cell line L428. However, gene expression profiling (GEP) of co-cultured HRS cells as well as tumor infiltration of matched CD4(+) T cells indicated cellular interactions. Moreover, matched CD4(+) T cells could be activated to kill CD30(+) HRS cells when redirected with a CD30-specific chimeric antigen receptor. Our work gives novel insights into the crosstalk between HRS and CD4(+) T cells, suggesting the latter as potent effector cells in the adoptive cell therapy of HL.

Entities:  

Keywords:  CD4+ T cells; Hodgkin and Reed-Sternberg (HRS) cells; Hodgkin lymphoma; MHC-II compatible donors; anti-tumor reaction; chimeric antigen receptor (CAR)

Year:  2016        PMID: 27471632      PMCID: PMC4938355          DOI: 10.1080/2162402X.2016.1160186

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  54 in total

1.  High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma.

Authors:  A van den Berg; L Visser; S Poppema
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

2.  On some Morbid Appearances of the Absorbent Glands and Spleen.

Authors: 
Journal:  Med Chir Trans       Date:  1832

Review 3.  The role of cytokines in classical Hodgkin lymphoma.

Authors:  Brian F Skinnider; Tak W Mak
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

4.  Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.

Authors:  L da Costa; C Renner; F Hartmann; M Pfreundschuh
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

5.  MHC class II and CD40 play opposing roles in dendritic cell survival.

Authors:  A McLellan; M Heldmann; G Terbeck; F Weih; C Linden; E B Bröcker; M Leverkus; E Kämpgen
Journal:  Eur J Immunol       Date:  2000-09       Impact factor: 5.532

6.  Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model.

Authors:  Asahi Ito; Takashi Ishida; Hiroki Yano; Atsushi Inagaki; Susumu Suzuki; Fumihiko Sato; Hisashi Takino; Fumiko Mori; Masaki Ri; Shigeru Kusumoto; Hirokazu Komatsu; Shinsuke Iida; Hiroshi Inagaki; Ryuzo Ueda
Journal:  Cancer Immunol Immunother       Date:  2008-12-02       Impact factor: 6.968

7.  In situ immunologic characterization of cellular constituents in lymph nodes and spleens involved by Hodgkin's disease.

Authors:  S Poppema; A K Bhan; E L Reinherz; M R Posner; S F Schlossman
Journal:  Blood       Date:  1982-02       Impact factor: 22.113

8.  Spindle-shaped CD163+ rosetting macrophages replace CD4+ T-cells in HIV-related classical Hodgkin lymphoma.

Authors:  Sylvia Hartmann; Christina Jakobus; Benjamin Rengstl; Claudia Döring; Sebastian Newrzela; Hans-Reinhard Brodt; Timo Wolf; Martin-Leo Hansmann
Journal:  Mod Pathol       Date:  2013-01-11       Impact factor: 7.842

9.  Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia.

Authors:  Yukihiro Miyazaki; Hiroshi Fujiwara; Hiroaki Asai; Fumihiro Ochi; Toshiki Ochi; Taichi Azuma; Takashi Ishida; Sachiko Okamoto; Junichi Mineno; Kiyotaka Kuzushima; Hiroshi Shiku; Masaki Yasukawa
Journal:  Blood       Date:  2013-05-02       Impact factor: 22.113

10.  Transcriptional reprogramming of mature CD4⁺ helper T cells generates distinct MHC class II-restricted cytotoxic T lymphocytes.

Authors:  Daniel Mucida; Mohammad Mushtaq Husain; Sawako Muroi; Femke van Wijk; Ryo Shinnakasu; Yoshinori Naoe; Bernardo Sgarbi Reis; Yujun Huang; Florence Lambolez; Michael Docherty; Antoine Attinger; Jr-Wen Shui; Gisen Kim; Christopher J Lena; Shinya Sakaguchi; Chizuko Miyamoto; Peng Wang; Koji Atarashi; Yunji Park; Toshinori Nakayama; Kenya Honda; Wilfried Ellmeier; Mitchell Kronenberg; Ichiro Taniuchi; Hilde Cheroutre
Journal:  Nat Immunol       Date:  2013-01-20       Impact factor: 25.606

View more
  5 in total

1.  Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58.

Authors:  Johanna Veldman; Lydia Visser; Magdalena Huberts-Kregel; Natasja Muller; Bouke Hepkema; Anke van den Berg; Arjan Diepstra
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

Review 2.  Current and Emerging Approaches to Study Microenvironmental Interactions and Drug Activity in Classical Hodgkin Lymphoma.

Authors:  Naike Casagrande; Cinzia Borghese; Donatella Aldinucci
Journal:  Cancers (Basel)       Date:  2022-05-14       Impact factor: 6.575

3.  CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma.

Authors:  Julia D S Hanauer; Benjamin Rengstl; Dina Kleinlützum; Johanna Reul; Anett Pfeiffer; Thorsten Friedel; Irene C Schneider; Sebastian Newrzela; Martin-Leo Hansmann; Christian J Buchholz; Alexander Muik
Journal:  Oncotarget       Date:  2018-01-12

4.  A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma.

Authors:  Bianca Schuhmacher; Benjamin Rengstl; Claudia Döring; Julia Bein; Sebastian Newrzela; Uta Brunnberg; Hans Michael Kvasnicka; Martine Vornanen; Ralf Küppers; Martin-Leo Hansmann; Sylvia Hartmann
Journal:  Oncotarget       Date:  2016-11-01

5.  Migration Properties Distinguish Tumor Cells of Classical Hodgkin Lymphoma from Anaplastic Large Cell Lymphoma Cells.

Authors:  Olga Goncharova; Nadine Flinner; Julia Bein; Claudia Döring; Emmanuel Donnadieu; Sandy Rikirsch; Marco Herling; Ralf Küppers; Martin-Leo Hansmann; Sylvia Hartmann
Journal:  Cancers (Basel)       Date:  2019-10-02       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.